cellectis.com (CLLS): Projected Future Earnings

Cellectis S.A. is developing allogeneic therapy with the support of global pharma behemoths, which mitigates risks. This consensus earnings forecast chart illustrates the trend of expectations, where the 0.01 level reflects the current magnitude. While robust cryo-logistics ensure drug delivery, the lack of revenue and high R&D expenses create a cash gap, forcing the company to raise external capital to maintain viability.

CLLS - Cellectis S.A. Expected Net Profit over the range 04/30/2024 - 04/30/2024

Analytical breakdowns for Cellectis S.A.

- price and consensus price forecast:

Price Chart Cellectis SA|CLLS - Average Forecast Price

- stock exchange capitalization data:

Market Capitalization Cellectis S.A.|CLLS - Full Takeover Company Value

- book capitalization indicators:

Accounting Value per Share Cellectis S.A.|CLLS - Total Stockholders' Equity|Market Cap to Net Assets Ratio cellectis.com|CLLS - Aggregate Asset Value

- debt level and financial liquidity data:

- earnings and market ratios statistics:

CLLS - Final Profit|Projected Future Earnings Cellectis S.A.|CLLS - Market Cap to Net Income Ratio|Forward P/E Multiple Cellectis SA|CLLS - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cellectis S.A.|CLLS - Operating profit before amortization|Net earnings per share (EPS TTM) Cellectis S.A.|CLLS - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months cellectis.com|CLLS - Earnings per share increase in current year|Expected earnings per share growth for next year Cellectis S.A.

Fundamental company analysis:CLLS, Cellectis S.A.

Cellectis S.A. is developing universal CAR-T cell therapy technology for oncology clinics, a process that requires colossal R&D investments. The trend in expected net profit, shaped by daily expert assessments, filters out market noise and reveals the real vector of the business's capitalization. Analyzing the level of priced-in profit allows investors to determine the asset's fair value and avoid overpaying for speculative price growth.

Key competitors